Skip to main content
Premium Trial:

Request an Annual Quote

Craig Mello, Andrew Fire, Jack Bowman, John Hodgman, Raymond Ruddon, Joseph Rubinfeld, Karen Gibson, and Nicolas Barthelemy


CytRx said last week that RNAi pioneer Craig Mello has joined the company’s scientific advisory board, as well as the SAB of subsidiary Araios.

Mello is a Howard Hughes Medical Institute investigator at the University of Massachusetts Medical School. He is best known for his discoveries about the RNAi mechanism as he worked in collaboration with Stanford University’s Andrew Fire.

Prior to his position at UMMS, Mello was a post-doctoral fellow at the Fred Hutchinson Cancer Research Center. Mello received a PhD from Harvard University and a BS from Brown University.

Antisense drug developer AVI BioPharma said this week that it has appointed Jack Bowman and John Hodgman, as well as Raymond Ruddon, to its board of directors.

Hodgman will also serve as chairman of the company’s board audit committee, AVI said.

According to AVI, Bowman has been chairman and CEO of NeoRx since 2003. Before this, he was company group chairman of Johnson & Johnson. He has also served as president of Lederle Laboratories and executive vice president of American Cyanamid.

Bowman currently serves as a director of Celgene and Targeted Genetics. He holds a BE from Western Washington University, said AVI.

Hodgman is president, CEO, and chairman of Cygnus, said AVI, and is a director of Immersion. Before working at Cygnus, where he previously was vice president of finance and CFO, Hodgman was president and CEO of Cygnus Diagnostics.

Hodgman holds a BS from Brigham Young University and an MBA from the University of Utah, said AVI.

Ruddon is currently adjunct professor of pharmacology at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, said AVI. Previously, Ruddon was corporate vice president and CSO at Johnson & Johnson, a company he first joined as director of the corporate office of science and technology.

He holds a BS from the University of Detroit and an MD from the University of Michigan.

AVI also announced this week that Joseph Rubinfeld has retired from its board. Rubinfeld will join the company’s scientific advisory board in the area of oncology.

Invitrogen said last week that it has appointed Karen Gibson as its senior vice president of information technology and CIO. The company also said that it has named Nicolas Barthelemy as its senior vice president of global operations.

Gibson was most recently vice president of global e-business and CIO for General Electric’s medical systems information technologies division, said Invitrogen. She holds a BS in computer technology from Purdue University and an MBA from Ohio University.

Barthelemy, Invitrogen said, was formerly vice president of manufacturing and general manager of the Research Triangle Park site for Biogen. He holds degrees from Ecole Sainte Genevieve and a MS from Ecole Superieure de Physiques et Chimie Industrielles. He also holds an MS from the University of California, Berkeley, according to Invitrogen.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.